Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort.

ABSTRACT:

Objectives

Early clinical trials showed promising outcomes with immune-checkpoint inhibitors (ICI) in a subset of patients with relapsed small-cell lung carcinoma (SCLC). The aim of this retrospective analysis was to assess the efficacy and safety of ICI for relapsed SCLC in a real-world patient population.

Methods

Nine cancer centres in Switzerland contributed data to this cohort. Responses were assessed by the local investigators using standard RECIST v1.1 criteria. Progression-free survival (PFS) and overall survival (OS) were analysed by the Kaplan-Meier method. Associations between potential predictive markers and survival endpoints were probed by Cox proportional hazards.

Results

Forty-five patients were included in the analysis. Median age was 63 years, 73% wer

SUBMITTER: Schmid S 

PROVIDER: S-EPMC11027633 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature